CY2016043I2 - Μεθοδος για τη θεραπευτικη αγωγη της πολλαπλης σκληρυνσης - Google Patents

Μεθοδος για τη θεραπευτικη αγωγη της πολλαπλης σκληρυνσης

Info

Publication number
CY2016043I2
CY2016043I2 CY2016043C CY2016043C CY2016043I2 CY 2016043 I2 CY2016043 I2 CY 2016043I2 CY 2016043 C CY2016043 C CY 2016043C CY 2016043 C CY2016043 C CY 2016043C CY 2016043 I2 CY2016043 I2 CY 2016043I2
Authority
CY
Cyprus
Prior art keywords
multiple sclerosis
therapeutic treatment
therapeutic
treatment
sclerosis
Prior art date
Application number
CY2016043C
Other languages
English (en)
Other versions
CY2016043I1 (el
Original Assignee
The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services, National Institutes Of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30000962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2016043(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services, National Institutes Of Health filed Critical The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services, National Institutes Of Health
Publication of CY2016043I1 publication Critical patent/CY2016043I1/el
Publication of CY2016043I2 publication Critical patent/CY2016043I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
CY2016043C 2002-06-28 2016-12-09 Μεθοδος για τη θεραπευτικη αγωγη της πολλαπλης σκληρυνσης CY2016043I2 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39302102P 2002-06-28 2002-06-28
PCT/US2002/038290 WO2004002500A1 (en) 2002-06-28 2002-11-27 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
PCT/US2003/020428 WO2004002421A2 (en) 2002-06-28 2003-06-27 Method for the treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
CY2016043I1 CY2016043I1 (el) 2017-04-05
CY2016043I2 true CY2016043I2 (el) 2017-04-05

Family

ID=30000962

Family Applications (2)

Application Number Title Priority Date Filing Date
CY2016043C CY2016043I2 (el) 2002-06-28 2016-12-09 Μεθοδος για τη θεραπευτικη αγωγη της πολλαπλης σκληρυνσης
CY20171100999T CY1119389T1 (el) 2002-06-28 2017-09-21 Μεθοδος για τη θεραπευτικη αγωγη της πολλαπλης σκληρυνσης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20171100999T CY1119389T1 (el) 2002-06-28 2017-09-21 Μεθοδος για τη θεραπευτικη αγωγη της πολλαπλης σκληρυνσης

Country Status (15)

Country Link
US (11) US7575742B2 (el)
EP (3) EP2314627B1 (el)
JP (8) JP2005535636A (el)
AU (3) AU2002368055B2 (el)
CA (3) CA2490804C (el)
CY (2) CY2016043I2 (el)
DK (2) DK2314627T3 (el)
ES (2) ES2637011T3 (el)
HK (1) HK1249850A1 (el)
HU (2) HUE036677T2 (el)
IL (2) IL165973A (el)
LU (1) LU93315I2 (el)
PT (2) PT2314627T (el)
SI (2) SI1539200T1 (el)
WO (2) WO2004002500A1 (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100854795B1 (ko) * 2001-04-26 2008-08-27 모션 테크놀로지즈 엘엘씨 롤러 트랙션 변속기 및 연속 가변 변속기의 속력비 조절을위한 장치
CA2490804C (en) * 2002-06-28 2016-12-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
US20060134750A1 (en) * 2004-03-10 2006-06-22 Pepgen Corporation Method of treatment using interferon-tau
EP1845925B1 (en) * 2005-01-12 2016-08-24 Biogen MA Inc. Method for delivering interferon-beta
WO2006089066A1 (en) * 2005-02-15 2006-08-24 Neuromolecular Pharmaceuticals, Inc. Combinations therapy for treatment of demyelinating conditions
CA2685596A1 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
RU2011111391A (ru) * 2008-08-28 2012-10-10 Эбботт Байотерапьютикс Корп. (Us) Способ лечения пациентов, страдающих рассеянным склерозом, антителами анти-il2r
US20110195049A1 (en) * 2008-10-13 2011-08-11 Biovista, Inc. Compositions and methods for treating multiple sclerosis
WO2010068923A2 (en) * 2008-12-12 2010-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Agents that selectively inhibit cd25 on dendritic cells or t cells and their use
AU2010286427A1 (en) * 2009-08-31 2012-03-08 Abbott Biotherapeutics Corp. Use of an immunoregulatory NK cell population for monitoring the efficacy of anti-IL-2R antibodies in multiple sclerosis patients
EP2560994B1 (en) * 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
US9133244B2 (en) 2011-01-18 2015-09-15 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
WO2013022972A1 (en) 2011-08-08 2013-02-14 Abbott Biotherapeutics Corporation Methods of treating progressive forms of multiple sclerosis
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
US10030058B2 (en) 2015-10-09 2018-07-24 Bioniz, Llc Modulating gamma-C-cytokine activity
WO2018027195A1 (en) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
DE102017104088A1 (de) * 2017-02-28 2018-08-30 L&O Hunting Group GmbH Integralschalldämpfer für einen Gewehrlauf
CA3137971A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
WO2021026362A1 (en) * 2019-08-07 2021-02-11 Edifice Health, Inc. Treatment of prevention of cardiovascular disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4819150A (en) 1985-04-05 1989-04-04 Unisys Corporation Array for simulating computer functions for large computer systems
US5336489A (en) 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US5011684A (en) * 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
US6051405A (en) * 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5695927A (en) 1988-03-31 1997-12-09 The University Of Arizona, Department Of Internal Medicine, Section Of Hematology And Oncology Monoclonal antibodies specific for HIV and the hybridomas for production thereof
FI895955A7 (fi) 1988-04-15 1989-12-13 Protein Design Labs Inc Il-2-reseptorispesifisiä "kimeerisiä" vasta-aineita
DE3815472A1 (de) * 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
US5152980A (en) 1988-05-19 1992-10-06 The Beth Israel Hospital Association Induction of tolerance to a foreign antigen IL-2 receptor-binding substances
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5620686A (en) * 1990-09-28 1997-04-15 British Technology Group Limited Antigen-antibody conjugates
US5840496A (en) * 1990-10-09 1998-11-24 Chiron Corporation Method for diagnosing endometrial cancer
FR2672291A1 (fr) 1991-01-31 1992-08-07 Inst Nat Sante Rech Med Composition d'anticorps diriges contre le recepteur de l'interleukine-2 humaine ou animale.
GB9115010D0 (en) 1991-07-11 1991-08-28 Wellcome Found Antibody
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571507A (en) 1992-02-25 1996-11-05 Seragen, Inc. Methods of treating diabetes
US5643756A (en) 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
EP0699077B1 (en) 1993-05-07 2001-10-31 Akzo Nobel N.V. Hiv immunogenic complexes
EP0714234B1 (en) 1993-08-27 2000-06-07 The Pillsbury Company Mechanical gas flushing system
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
US6833135B1 (en) * 1997-08-06 2004-12-21 Laboratorio Medinfar Produtos Farmaceuticos, Lda. DNA integration into “Mycobacterium spp.” genome by trans-complementation using a site-specific integration system
WO2000025816A1 (en) 1998-10-30 2000-05-11 The University Of Miami Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US6899869B2 (en) * 2000-04-25 2005-05-31 Tomoaki Hoshino Method of preparing an animal model for interstitial pneumonia
CZ20032672A3 (cs) * 2001-04-06 2003-12-17 University Of Bristol CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy
CA2490804C (en) * 2002-06-28 2016-12-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
AU2003251633A1 (en) 2002-07-01 2004-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Il-21 as a regulator of immunoglobin production

Also Published As

Publication number Publication date
AU2008212004A1 (en) 2008-09-25
AU2003247813A1 (en) 2004-01-19
US20150337044A1 (en) 2015-11-26
PT1539200E (pt) 2014-08-25
EP3269377A1 (en) 2018-01-17
US20130095069A1 (en) 2013-04-18
AU2002368055A1 (en) 2004-01-19
CA2490186C (en) 2014-04-15
CY2016043I1 (el) 2017-04-05
CA2490186A1 (en) 2004-01-08
US20170190779A1 (en) 2017-07-06
US8454965B2 (en) 2013-06-04
US8636997B2 (en) 2014-01-28
WO2004002500A1 (en) 2004-01-08
EP2314627A2 (en) 2011-04-27
ES2637011T3 (es) 2017-10-10
CA2490804C (en) 2016-12-06
SI2314627T1 (sl) 2017-10-30
IL165973A (en) 2015-10-29
JP2010132660A (ja) 2010-06-17
IL165973A0 (en) 2006-01-15
US20040109859A1 (en) 2004-06-10
JP2006508039A (ja) 2006-03-09
DK1539200T3 (da) 2014-06-30
DK2314627T3 (en) 2017-10-23
JP2016145220A (ja) 2016-08-12
PT2314627T (pt) 2017-08-29
AU2002368055B2 (en) 2008-09-18
EP1539200A2 (en) 2005-06-15
WO2004002421A3 (en) 2004-09-02
EP1539200A4 (en) 2007-11-07
HK1249850A1 (en) 2018-11-16
SI1539200T1 (sl) 2014-09-30
HK1074769A1 (en) 2005-11-25
US20150010477A1 (en) 2015-01-08
AU2003247813C1 (en) 2010-07-22
JP5905534B2 (ja) 2016-04-20
US20050249704A1 (en) 2005-11-10
US7258859B2 (en) 2007-08-21
ES2474718T3 (es) 2014-07-09
US7575742B2 (en) 2009-08-18
LU93315I2 (fr) 2017-01-26
EP1539200B1 (en) 2014-05-28
JP2014221813A (ja) 2014-11-27
CA2490804A1 (en) 2004-01-08
HUE036677T2 (hu) 2018-07-30
AU2003247813B2 (en) 2008-06-05
JP2011157378A (ja) 2011-08-18
JP2013139478A (ja) 2013-07-18
AU2008212004B2 (en) 2010-10-21
US20190002575A1 (en) 2019-01-03
US20090175823A1 (en) 2009-07-09
JP2013032372A (ja) 2013-02-14
EP2314627A3 (en) 2011-05-11
CY1119389T1 (el) 2018-02-14
US20180237532A1 (en) 2018-08-23
WO2004002421A2 (en) 2004-01-08
US20130017152A1 (en) 2013-01-17
HUS1600050I1 (hu) 2017-06-28
US8298525B2 (en) 2012-10-30
EP2314627B1 (en) 2017-07-26
JP2005535636A (ja) 2005-11-24
IL241920A0 (en) 2015-11-30
US20080038275A1 (en) 2008-02-14
CA2844639A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
CY2016043I1 (el) Μεθοδος για τη θεραπευτικη αγωγη της πολλαπλης σκληρυνσης
CY2013021I2 (el) Συνθεσεις για τη θεραπευτικη αγωγη γαστροεντερικων διαταραχων
NO20052914D0 (no) Terapeutiske forbindelser
EP1482962A4 (en) METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX)
CY2013039I1 (el) Φθοροϋποκατεστημενη ωμεγα-καρβοξυαρυλ διφαινυλ ουρια για τη θεραπεια και προληψη ασθενειων και καταστασεων
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
NO20044054L (no) Administrering av midler for behandling av betennelse
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
NO20044402L (no) Kombinasjonsbehandling av kemokine-medierte sykdommer
EP1534074A4 (en) POLYTHERAPY FOR THE TREATMENT OF OBESITY
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
NO20040353L (no) Ny terapeutsk metode
FI20020479A7 (fi) Pintakäsittelyprosessi
NO20045554L (no) Fremgangsmate for behandling av diabetes
EP1651237A4 (en) METHODS OF TREATING DERMATOLOGICAL DISORDERS
FI20020817A7 (fi) Pintakäsittelyprosessi
DK1553950T3 (da) Terapeutisk behandling
DE60229887D1 (de) Oberflächenbehandlungssystem
NO20033160D0 (no) Anordning for behandling av gravann
EP1511474A4 (en) PROCESSING PROCESS
EE00323U1 (et) Kohanaha töötlemise meetod
SE0104249D0 (sv) Method of treatment
AUPS216802A0 (en) Method for the treatment of multiple sclerosis
AUPS219602A0 (en) Method for the treatment of multiple sclerosis